Skip to main content
Clinical Trials/JPRN-UMIN000041639
JPRN-UMIN000041639
Completed
N/A

Prospective observational study to evaluate appropriate dose and efficacy of cephamycin and oxacephem for invasive UTI due to ESBL-E. coli - CMZ/FMOX for ESBL-E. coli UTI

CGM0 sites78 target enrollmentSeptember 1, 2020
Conditionsinvasive UTI

Overview

Phase
N/A
Intervention
Not specified
Conditions
invasive UTI
Sponsor
CGM
Enrollment
78
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 1, 2020
End Date
December 31, 2021
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
CGM

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients with a history of invasive urinary tract infection within 4 weeks prior to onset \- Patients with concomitant use of antimicrobial agents (beta\-lactams, aminoglycosides, fluoroquinolones, ST\-fusions, colistin, tigecycline, minomycin, doxycycline, nitrofurantoin, and fosfomycin) that may be effective against ESBL\-producing E. coli in addition to the study drug. \- Persons with a history of hypersensitivity to cephem and carbapenem antibiotics \- Dialysis patients (hemodialysis and peritoneal dialysis) \- Other items that the principal investigator deems inappropriate for inclusion in the research

Outcomes

Primary Outcomes

Not specified

Similar Trials